Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Krystal Biotech (KRYS) Restructuring Costs (2022 - 2024)

Krystal Biotech (KRYS) has disclosed Restructuring Costs for 3 consecutive years, with $12.5 million as the latest value for Q3 2024.

  • Quarterly Restructuring Costs changed N/A to $12.5 million in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $12.5 million through Jun 2025, down 85.71% year-over-year, with the annual reading at $37.5 million for FY2024, 200.0% up from the prior year.
  • Restructuring Costs hit $12.5 million in Q3 2024 for Krystal Biotech, down from $37.5 million in the prior quarter.
  • In the past five years, Restructuring Costs ranged from a high of $37.5 million in Q4 2023 to a low of $12.5 million in Q1 2023.
  • Historically, Restructuring Costs has averaged $21.4 million across 3 years, with a median of $12.5 million in 2023.
  • Biggest five-year swings in Restructuring Costs: crashed 50.0% in 2023 and later skyrocketed 200.0% in 2024.
  • Year by year, Restructuring Costs stood at $25.0 million in 2022, then skyrocketed by 50.0% to $37.5 million in 2023, then plummeted by 66.67% to $12.5 million in 2024.
  • Business Quant data shows Restructuring Costs for KRYS at $12.5 million in Q3 2024, $37.5 million in Q2 2024, and $12.5 million in Q1 2024.